|

WEF-001 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: MMAE-Drug Conjugate

Pipeline

Phase 1/2: 1

Top Sponsors

  • Auricula Biosciences Inc.1

Indications

  • Advanced or Metastatic KRAS-mutant Tumor1
  • Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer1
  • Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer1
  • Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma1
  • Advanced Solid Tumors1

Dallas, Texas1 trial

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

NEXT Oncology Dallas

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.